Begin main content

Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines

Published on: September 21, 2016
Project Number: RC0768-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness and safety of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of adult patients with chronic non-cancer pain or neuropathic pain?
  2. What are the evidence-based guidelines relating to the use of delta-9-tetrahydrocannabinol/cannabidiol for adult patients with chronic non-cancer pain or neuropathic pain?

Key Message

Five systematic reviews, including two with meta-analyses, were identified relating to the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol (THC:CBD) buccal spray for the treatment of chronic neuropathic or non-cancer pain. Based on the identified published literature, THC:CBD buccal spray may be associated with favourable short-term patient outcomes, including reduced levels of perceived pain and a good tolerability, when compared with placebo therapy. However, sustained benefit of short-term clinical outcomes and safety over a longer term is unclear, and the clinical effectiveness of THC:CBD oral spray in comparison with other pharmacologic treatments is currently lacking.One evidence-based guideline was identified that recommends third-line use of THC:CBD buccal spray for patients uncontrolled on drug therapy in the management of chronic neuropathic pain.

Tags

cannabidiol, chronic pain, neuralgia, tetrahydrocannabinol, other miscellaneous topics, nabiximols, nabidiolex, dronabinol, Pain, Pains, sativex